New drug cocktail aims to stop bile duct cancer from returning after surgery
NCT ID NCT04669496
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether giving a combination of an immunotherapy drug (toripalimab), a targeted therapy (lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. The trial includes 178 patients whose cancer is removable but has features that make it likely to come back. The goal is to see if this pre-surgery treatment can delay or prevent recurrence and extend survival compared to surgery alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (PD-1 antibody), lenvatinib, and GEMOX chemotherapy
What this could lead to
If successful, this combination given before surgery could lower the chance of bile duct cancer coming back and improve long-term survival for high-risk patients.
What could go wrong
This is an early-to-mid stage trial with only 178 participants, so results may not apply to everyone. The drug combo can cause significant side effects, and it's not yet proven to be better than standard surgery alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital
Shanghai, Shanghai Municipality, 200032, China